Oxygenta pharmaceutical has filed its quarterly compliance certificate for securities dematerialization with BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The certificate covers the quarter ended March 31, 2026, and was submitted on April 15, 2026.

Regulatory Compliance Details

The compliance certificate was filed under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates companies to provide details of securities dematerialized during each quarter to all stock exchanges where their shares are listed.

Company Secretary Certification

The certificate was signed by Kumkum Bajaj, Company Secretary and Compliance Officer (Membership No.: ACS76548), who digitally signed the document on April 15, 2026. The filing confirms that all required details of securities dematerialized during the quarter have been furnished to stock exchanges where the company's shares are listed.

RTA Verification

Venture Capital and Corporate Investments Private Limited, serving as the company's Registrar and Transfer Agent (RTA), provided verification through a letter dated April 3, 2026. The RTA confirmed compliance with dematerialization procedures and proper record maintenance.

Depository Operations

The RTA certified that securities received for dematerialization were properly processed according to regulatory requirements. The verification process included:

• Mutilation and cancellation of physical certificates after due verification
• Update of depository names in company records as registered owners
• Completion of processing within 15 days of receiving valid Dematerialization Request Form (DRF) and share certificates
• Furnishing details to relevant stock exchanges

Both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) were updated as registered owners in the company's records, ensuring compliance with depository regulations.

Oxygenta Pharmaceutical Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025, revealing continued operational challenges despite revenue growth. The pharmaceutical manufacturer reported a net loss of ₹484.30 lakhs for Q3 FY26, representing a 23.28% increase in losses compared to ₹392.82 lakhs in the corresponding quarter of the previous year.

Financial Performance Overview

The company's quarterly performance showed mixed results, with revenue growth offset by increased operational losses. Despite achieving higher sales, the company faced significant cost pressures that impacted profitability.

Cost Structure Analysis

The company's expense structure revealed several pressure points during the quarter. Cost of materials consumed stood at ₹3,117.03 lakhs in Q3 FY26 compared to ₹3,760.65 lakhs in Q3 FY25. However, other operational expenses increased significantly, including finance costs which rose to ₹139.08 lakhs from ₹38.83 lakhs in the previous year quarter.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Oxygenta Pharmaceutical reported revenue from operations of ₹6,336.79 lakhs compared to ₹5,983.21 lakhs in the corresponding period of the previous year. The net loss for the nine-month period widened to ₹1,591.42 lakhs from ₹814.54 lakhs in the previous year.

Corporate Governance Updates

The Board of Directors, during their meeting held on February 4, 2026, approved the re-constitution of the Internal Complaints Committee under The Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013. The committee comprises eight members including Mrs. G. Durga Bhavani as Presiding Officer and Ms. D. Rajeswari as External Member.

Operational Challenges

The company acknowledged ongoing challenges in identifying MSME creditors and implementing bill-to-bill adjustment processes. Management stated they are actively working to complete supplier identification through self-declaration forms and are committed to achieving full compliance and transparency in reporting. The company operates in a single segment of pharmaceutical product manufacturing, with paid-up equity share capital of ₹3,698.35 lakhs.